First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

PAN  Yi; TAN  Pei-xin

doi:10.12019/j.issn.1671-5144.2016.04.012

PAN Yi, TAN Pei-xin. First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. Journal of Evidence-Based Medicine, 2016, 16(4): 230-232. DOI: 10.12019/j.issn.1671-5144.2016.04.012

Citation:

PAN Yi, TAN Pei-xin. First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. Journal of Evidence-Based Medicine, 2016, 16(4): 230-232. DOI: 10.12019/j.issn.1671-5144.2016.04.012

Citation:

PAN Yi, TAN Pei-xin. First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. Journal of Evidence-Based Medicine, 2016, 16(4): 230-232. DOI: 10.12019/j.issn.1671-5144.2016.04.012

First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

PAN Yi,
TAN Pei-xin

Graphical Abstract

Abstract

FullText(HTML)

References (10)

First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Catalog

Export File

Citation

Format

Content